VEXAS Syndrome Clinical Features and Treatment Outcomes in a Chinese Cohort of 16 Patients
Small study links UBA1 gene variants to blood and inflammatory issues in China
This retrospective cohort study of 16 Chinese patients describes main clinical features and treatment responses in VEXAS syndrome. Constitut…
A specific genetic change called a UBA1 variant was found in 81 percent of patients in China with blood disorders and inflammation affecting…
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation
Early trial explores itacitinib for stem cell transplant patients with blood disorders
This Phase IIa trial evaluated itacitinib combined with tacrolimus and sirolimus in patients with acute leukemia, myelodysplastic syndrome, …
A new trial adds itacitinib to standard care for stem cell transplant patients with blood disorders to help prevent graft-versus-host diseas…
Case report: Low-intensity chemotherapy achieves remission in PMF transformed to MPAL
Single case report describes treatment for rare leukemia transformation in elderly patient
A case report describes a 75-year-old female with JAK2V617F-positive primary myelofibrosis that transformed to mixed phenotype acute leukemi…
A 75-year-old woman with rare leukemia transformation from blood disorder achieved remission after two cycles of low-intensity chemotherapy.